2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1716

Higher Frequency and Severity of Coronary Plaques on Coronary CT Angiography in Psoriatic Arthritis Patients without Symptoms of Coronary Artery Disease Compared to Controls
Abstract Number: 2771

Higher Incident Rates of Comorbidities in Patients with Psoriatic Arthritis (PsA) Compared to Controls
Abstract Number: 556

Higher Multi Biomarker Disease Activity Scores Foreshadow Greater Longitudinal Improvement in RA Disease Activity
Abstract Number: 2462

Higher Number of Tender Than Swollen Joint Count Is Associated to Higher Patient Reported Outcomes and Composite Scores As Well As Reduced Probability of Obtaining Remission: Results from a One-Year Follow-up Study of Established RA Patients Starting Bdmards
Abstract Number: 3099

Higher Prevalence and Severity of Coronary Atherosclerosis in Psa Patients
Abstract Number: 498

Higher Serum Heavy Metals Concentrations Are Associated with Rheumatoid Arthritis : A Study of the Korean National Health and Nutrition Examination Survey (KNHANES)
Abstract Number: 723

Hip Disease Treatment and Progression in Ankylosing Spondylitis
Abstract Number: 315

Hip Inflammation MRI Scoring System (HIMRISS) to Predict Response to Hyaluronic Acid (HAnox-M-XL) Injection in Hip Osteoarthritis
Abstract Number: 276

Histological Study on the Expression of Transcriptional Intermediary Factor 1 (TIF1) in the Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 2355

Histology of Bone Marrow Lesions in Osteoarthritis: A Systematic Literature Review
Abstract Number: 1566

Histone Lysine Methylation and STAT3 Differentially Regulate Constitutive and IL-6-Induced MMPs Gene Activation in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 182

Histone Methylation in γδ T Cells As a Biomarker of Behcet’s Disease Activity
Abstract Number: 2838

Histopatholgic Predictors of Poor Renal Outcomes in a Multi-Ethnic Cohort
Abstract Number: 2256

Histopathologic Features and Tissue Interferon-Response Gene Scoring of Lesional Skin Samples for Diagnosis in Autoinflammatory Disorders
Abstract Number: 1066

History of Lupus Nephritis Is an Independent Risk Factor for Thrombosis in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].